Industry
Biotechnology
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Loading...
Open
2.55
Mkt cap
14M
Volume
26K
High
2.61
P/E Ratio
-0.89
52-wk high
13.61
Low
2.50
Div yield
N/A
52-wk low
2.26
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 10:38 am
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 03, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 3:55 pm
Portfolio Pulse from Vandana Singh
September 26, 2024 | 2:53 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 11:51 am
Portfolio Pulse from Benzinga Newsdesk
September 20, 2024 | 10:35 am
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 11:58 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.